Overview

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status:
Active, not recruiting
Trial end date:
2024-08-23
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Phase:
Phase 2
Details
Lead Sponsor:
InSilico Medicine Hong Kong Limited